Cadazolid (formerly ACT-179811) is a novel oxazolidinone with in vitro activity against methicillin-resistant *S. aureus* and recently completed Phase II clinical trials. The drug was 16- to 32-fold more potent than linezolid (MIC₅₀/₉₀, 0.25–0.5/1 µg/mL) when tested against non-wildtype (linezolid MIC values of ≤2 µg/mL) when tested against *S. aureus* and *S. epidermidis* (Table 1). When tested against non-wildtype isolates with characterized linezolid resistance mechanisms and inhibited all isolates (Table 1). A direct comparison between cadazolid and linezolid showed that the former (62—not less than 128-fold more potent then linezolid when tested against *S. epidermidis* non-wildtype strains (Table 2).

**RESULTS**

**ABSTRACT**

**INTRODUCTION**

**MATERIALS AND METHODS**

**RESULTS**

**CONCLUSIONS**

**ACKNOWLEDGEMENT**

**REFERENCES**